R&S GROUP HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.8 CHF | -0.92% |
|
+1.41% | +1.89% |
| May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
| May. 03 | Reliance Insider Sold Shares Worth $1,449,067, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 274.6 | 301.6 | - | - |
| Enterprise Value (EV) 1 | 274.6 | 282 | 273.5 | 263.6 |
| P/E ratio | 26.5 x | 11.5 x | 11.2 x | 11.1 x |
| Yield | - | 3.24% | 3.38% | 3.21% |
| Capitalization / Revenue | 1.27 x | 1.36 x | 1.24 x | 1.16 x |
| EV / Revenue | 1.27 x | 1.27 x | 1.13 x | 1.01 x |
| EV / EBITDA | 8.85 x | 7.11 x | 6.85 x | 6.39 x |
| EV / FCF | - | 13.1 x | 13.2 x | 14 x |
| FCF Yield | - | 7.66% | 7.6% | 7.13% |
| Price to Book | - | 5.78 x | 4.38 x | 3.49 x |
| Nbr of stocks (in thousands) | 25,901 | 27,929 | - | - |
| Reference price 2 | 10.60 | 10.80 | 10.80 | 10.80 |
| Announcement Date | 4/17/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 216.9 | 222.1 | 242.6 | 259.8 |
| EBITDA 1 | - | 31.02 | 39.67 | 39.96 | 41.24 |
| EBIT 1 | - | 28.68 | 37.22 | 37.08 | 37.65 |
| Operating Margin | - | 13.22% | 16.76% | 15.28% | 14.49% |
| Earnings before Tax (EBT) | 6.023 | - | - | 35.6 | 34.2 |
| Net income | 4.252 | - | - | 28.8 | 27.4 |
| Net margin | - | - | - | 11.87% | 10.55% |
| EPS 2 | - | 0.4000 | 0.9410 | 0.9606 | 0.9756 |
| Free Cash Flow 1 | - | - | 21.6 | 20.8 | 18.8 |
| FCF margin | - | - | 9.73% | 8.57% | 7.24% |
| FCF Conversion (EBITDA) | - | - | 54.45% | 52.05% | 45.59% |
| FCF Conversion (Net income) | - | - | - | 72.22% | 68.61% |
| Dividend per Share 2 | - | - | 0.3504 | 0.3654 | 0.3467 |
| Announcement Date | 11/8/23 | 4/17/24 | - | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 19.7 | 28.1 | 38 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 21.6 | 20.8 | 18.8 |
| ROE (net income / shareholders' equity) | - | - | 48.2% | 44.6% | 35.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 1.870 | 2.470 | 3.100 |
| Cash Flow per Share 2 | - | - | 1.590 | 1.420 | 1.330 |
| Capex 1 | - | - | 7.5 | 6.53 | 6.7 |
| Capex / Sales | - | - | 3.38% | 2.69% | 2.58% |
| Announcement Date | 11/8/23 | 4/17/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
10.8
CHF
Average target price
12.3
CHF
Spread / Average Target
+13.89%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.89% | 333M | |
| +4.05% | 44.77B | |
| +161.13% | 5.01B | |
| +5.27% | 3.04B | |
| -0.38% | 2.87B | |
| +97.93% | 1.25B | |
| -27.93% | 1.16B | |
| +65.52% | 1.07B | |
| -8.64% | 997M | |
| -13.47% | 929M |
- Stock Market
- Equities
- RSGN Stock
- Financials R&S Group Holding AG